Identification of Altered Transcripts and Pathways in Triple Negative Breast Cancer

Abstract Triple negative breast cancer (TNBC) is a breast cancer subtype characterised by lack of oestrogen receptor, progesterone receptor, and human epidermal growth factor receptor, and by worse prognosis than other cancer types. The aim of this study was to identify hub genes and molecular pathways for possible prognostic markers for TNBC. Nineteen breast cancer transcriptomes were sequenced using Illumina platform and analysed to identify differentially expressed genes in the TNBC subtype. Gene ontology enrichment analysis was conducted using the ToppGene tool. Then, the STRING online database was used for protein-protein interaction (PPI) network construction. Cytohubba and the MCODE plug-in were used to screen functional modules and hub genes. In total, 229 DEGs were identified by differential gene expression analysis in the TNBC group. Eight genes were screened out from the PPI network — FOXA1, ESR1, TFF1, GATA3, TFF3, AR, SLC39A6, COL9A1. In conclusion, this study indicates that the molecular subtype specific gene expression pattern provides useful information for targeted, biomarker-driven treatment options.

[1]  G. Tse,et al.  Sry‐related high‐mobility‐group/HMG box 10 (SOX10) as a sensitive marker for triple‐negative breast cancer , 2020, Histopathology.

[2]  Jie Wu,et al.  Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[3]  Dong-Joo Cheon,et al.  The Role of the Extracellular Matrix in Cancer Stemness , 2019, Front. Cell Dev. Biol..

[4]  Xiaofeng Dai,et al.  FOXA1 is Prognostic of Triple Negative Breast Cancers by Transcriptionally Suppressing SOD2 and IL6 , 2019, International journal of biological sciences.

[5]  D M Parkin,et al.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods , 2018, International journal of cancer.

[6]  Xiaoxuan Tian,et al.  Identification of Key Genes and Pathways in Triple-Negative Breast Cancer by Integrated Bioinformatics Analysis , 2018, BioMed research international.

[7]  F. Puglisi,et al.  Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. , 2018, Cancer treatment reviews.

[8]  G. Romieu,et al.  Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers , 2018, British Journal of Cancer.

[9]  Y. Seto,et al.  Serum TFF1 and TFF3 but not TFF2 are higher in women with breast cancer than in women without breast cancer , 2017, Scientific Reports.

[10]  Xu Xiaoli,et al.  Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes , 2017, Journal of Clinical Pathology.

[11]  K. Hirakawa,et al.  Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer , 2017, Cancers.

[12]  J. Balko,et al.  Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease , 2016, Nature Reviews Clinical Oncology.

[13]  Sanghui Park,et al.  Expression patterns of GATA3 and the androgen receptor are strongly correlated in patients with triple-negative breast cancer. , 2016, Human pathology.

[14]  Harold L. Moses,et al.  Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection , 2016, PloS one.

[15]  P. Steeg,et al.  Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism , 2015, Oncogene.

[16]  J. Taube,et al.  Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas. , 2013, Human pathology.

[17]  V. Čapkun,et al.  Expression of androgen receptors in triple negative breast carcinomas. , 2013, Acta histochemica.

[18]  R. Elledge,et al.  Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up , 2012, Breast Cancer Research and Treatment.

[19]  David S Morrison,et al.  Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women , 2012, BMJ : British Medical Journal.

[20]  R. Tamimi,et al.  Androgen Receptor Expression in Breast Cancer in Relation to Molecular Phenotype: Results from the Nurses’ Health Study , 2011, Modern Pathology.

[21]  Zhihua Liu,et al.  ER regulates an evolutionarily conserved apoptosis pathway. , 2010, Biochemical and biophysical research communications.

[22]  E. Lam,et al.  Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours , 2009, Breast Cancer Research.

[23]  Jing Chen,et al.  ToppGene Suite for gene list enrichment analysis and candidate gene prioritization , 2009, Nucleic Acids Res..

[24]  Piyush B. Gupta,et al.  Contributions of estrogen to ER-negative breast tumor growth , 2006, The Journal of Steroid Biochemistry and Molecular Biology.

[25]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.